Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
about
KASL clinical practice guidelines: management of chronic hepatitis BClinical impact of occult hepatitis B virus infection in immunosuppressed patientsHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedEntecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Chemotherapy-related reactivation of hepatitis B infection: updates in 2013.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Long-term disease control by pomalidomide-/dexamethasone-based therapy in a patient with advanced multiple myeloma: a case report and review of the literature.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Hepatitis B virus reactivation associated with anti-neoplastic therapy.A drug safety evaluation of rituximab and risk of hepatitis B.Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Occult HBV infection in the oncohematological setting.Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era.The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumoursEfficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies.Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.Management of hepatitis B virus-related acute liver failure.Occult hepatitis B: clinical viewpoint and management.Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.Hepatitis B virus reactivation and liver function after chemoembolization for hepatocellular carcinoma: How is it different from systemic chemotherapy?Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.Case report: detection of a hepatitis B surface antigen variant emerging in an elderly patient after an ischemic cerebral vascular accident.
P2860
Q26752475-3E8BC84D-19FC-4E80-8A9E-1A27B60187AEQ27006996-4F4FCA9B-340A-4BFA-AA36-272AE191ACE6Q28076703-745893E4-2928-4B20-8C01-808B18C1F8A3Q34333145-0A700401-A7BD-4741-9C1D-263E6F6E7B23Q34397738-43FD005D-4ABD-4B94-9F6A-DC8CAABF5C14Q34404991-69B87AAE-E3B2-4DCD-950A-3F52FEC13B2DQ35037621-D74161F9-1A76-4B24-8EAC-F5DEF124BCF1Q35592482-BAA9E508-8514-4076-A97C-5163785FFE5AQ36153966-6BF3BFDC-E7B1-4D48-87D5-94135D1ACB89Q36368747-869D6C3A-A149-4698-93ED-F45C39C3D908Q38013661-584C9C39-4203-494C-BF86-C8515E53E1BFQ38047362-4FC1B551-B25B-4C55-97BC-DBA98EAB249BQ38211373-A8D6E9C6-4996-45C8-A91E-E56947DBE495Q38218566-97BC252F-A156-4EFF-BF32-9DF2D7F9F8A7Q38253568-BD6CE6D9-829A-41EB-8D7E-B8BAD4A48219Q38397403-85B2E62B-7012-484E-AC23-B2F5EAC3DB50Q38755178-3AB87C2D-1828-48A0-9EFE-E63E0EAC1C45Q38807875-DAD8A629-FBE6-4E79-B5AA-6852F9276B9BQ39643993-C852239A-5158-4EE2-B808-47A4C31C0849Q40727234-C1A1BC9A-7FEC-4D84-B284-F9483468E357Q40859411-71ADF45D-0648-4EF1-8FED-404BCE9624DEQ41252998-C4ADE4BF-D72E-4850-A1FB-9F83D52D4969Q41651814-CEE2E94F-EFD9-4686-89D8-55C58A287F87Q42224704-983DEA62-2C26-40B4-A31F-B6A847C0C162Q42240045-DBEF6289-C8C9-43F9-9591-5680FB5E171EQ43223881-F9033064-E263-4FB4-A496-120D18C12D5FQ44359185-E486785D-5C71-420C-8A0E-422D7CC3BADCQ45268408-7369EC66-C1A7-4DDB-B33E-2C08DCF81045Q45349329-5F8359C4-8C1D-4405-9CA2-AAA825EAB531Q46242353-1A2D8820-2116-4424-B7D5-8249932D5EA6Q48329633-4EDE9D26-808F-4644-939B-836F65F8A8B8
P2860
Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Clinical and virological facto ...... ll transplantation for cancer.
@en
Clinical and virological facto ...... ll transplantation for cancer.
@nl
type
label
Clinical and virological facto ...... ll transplantation for cancer.
@en
Clinical and virological facto ...... ll transplantation for cancer.
@nl
prefLabel
Clinical and virological facto ...... ll transplantation for cancer.
@en
Clinical and virological facto ...... ll transplantation for cancer.
@nl
P2093
P921
P1476
Clinical and virological facto ...... ll transplantation for cancer.
@en
P2093
A Charbonnier
A M Stoppa
C Chabannon
P304
P356
10.1111/J.1365-2893.2009.01239.X
P577
2010-11-01T00:00:00Z